Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 2
Posts 75
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
Stocks Expected To Rise In Low-volume Holiday Week
Stocks will likely climb higher in the traditionally low-volume Christmas-foreshortened trading week following last week's big boost from a dovish Federal Reserve.
Top Equities Stories Of The Day
Deezer Names New CEO Before Full U.S. Launch
UK Public Finances Get Boost From Forex Fines--Update
Asia Stocks Close Mostly Higher As Crude, Ruble Rise
U.K. Stocks Bounce Up At Start Of Holiday-shortened Week
Ally Financial Exits TARP as Treasury Sells Remaining Stake -- 3rd Update
Suspect in Shooting of New York Officers Had Troubled History -- 2nd Update
U.K. Police Arrest Man in Forex Market Manipulation Probe -- Update
U.S. Move to Normalize Cuba Ties Boosts Firms' Asset Claims
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 184980 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist